secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001641172-25-009664
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q1 revenue $32.9M (+18% YoY), net income $58K, raises FY2025 guidance to $127-131M
--------------------------------------------------------------------------------

- Revenue $32.9M, up 18% vs Q1 2024; net income $58K vs net loss $4.4M prior year.
- Adjusted EBITDA $3.0M vs loss $1.0M; cash from operations $1.3M vs use of $5.8M.
- FY2025 revenue guidance raised to $127-131M (8-12% growth) from prior $126-130M.
- Launched Trivium next-generation DBM allograft; elevated Mark Schallenberger to COO.
- Terminated investor rights agreement with OrbiMed; completed secondary share sale led by Nantahala.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000164117225009664/0001641172-25-009664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000164117225009664/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer